Pharmaceutical giant GSK revealed on Tuesday that a recent trial on its endometrial cancer drug candidate showed the potential of the medication when used alongside chemotherapy.
GSK stated a Phase III RUBY clinical trial demonstrated the potential of its Jemperli drug – showing a 72% and 36% reduction in the risk of disease progression or death in the dMMR/MSI-H population and overall patient population, respectively
The FTSE 100-listed group also said it had witnessed a “clinically meaningful overall survival trend” in interim analysis of the results and highlighted that regulatory submissions were already planned for the first half of 2023.
GSK vice president Hesham Abdullah said: “These positive results from the RUBY trial bring us one step closer to addressing the significant unmet needs of endometrial cancer patients and add to the growing body of evidence on dostarlimab, strengthening our belief in its potential to transform cancer treatment as a backbone immuno-oncology therapy.”
As of 0915 BST, GSK shares were up 0.45% at 1,430.0p.
Reporting by Iain Gilbert at Sharecast.com
